• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TLSI

    TriSalus Life Sciences Inc.

    Subscribe to $TLSI
    $TLSI
    Medical Specialities
    Health Care

    IPO Year: 2021

    Exchange: NASDAQ

    Recent Analyst Ratings for TriSalus Life Sciences Inc.

    DatePrice TargetRatingAnalyst
    2/13/2025Buy
    Lake Street
    12/17/2024$10.00Overweight
    Cantor Fitzgerald
    11/11/2024$11.00Buy
    ROTH MKM
    10/25/2024$12.50Outperform
    Northland Capital
    9/16/2024$10.00Outperform
    Oppenheimer
    5/30/2024$12.00Buy
    Canaccord Genuity
    See more ratings

    TriSalus Life Sciences Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on TriSalus Life Sciences

      Lake Street initiated coverage of TriSalus Life Sciences with a rating of Buy

      2/13/25 8:48:50 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • Cantor Fitzgerald initiated coverage on TriSalus Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of TriSalus Life Sciences with a rating of Overweight and set a new price target of $10.00

      12/17/24 8:31:30 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • ROTH MKM initiated coverage on TriSalus Life Sciences with a new price target

      ROTH MKM initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00

      11/11/24 7:48:55 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • Northland Capital initiated coverage on TriSalus Life Sciences with a new price target

      Northland Capital initiated coverage of TriSalus Life Sciences with a rating of Outperform and set a new price target of $12.50

      10/25/24 9:12:38 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • Oppenheimer initiated coverage on TriSalus Life Sciences with a new price target

      Oppenheimer initiated coverage of TriSalus Life Sciences with a rating of Outperform and set a new price target of $10.00

      9/16/24 7:49:11 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • Canaccord Genuity initiated coverage on TriSalus Life Sciences with a new price target

      Canaccord Genuity initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $12.00

      5/30/24 8:12:07 AM ET
      $TLSI
      Medical Specialities
      Health Care

    TriSalus Life Sciences Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Young James Emmett bought $33,900 worth of shares (6,000 units at $5.65) (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/6/25 6:09:01 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T bought $51,754 worth of shares (10,040 units at $5.15), increasing direct ownership by 2% to 444,259 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      1/31/25 5:54:39 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T was granted 40,000 shares and bought $50,303 worth of shares (9,542 units at $5.27), increasing direct ownership by 13% to 434,219 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      1/29/25 6:15:05 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Chief Manuf, Strategy&Bus Dev. Murphy Sean was granted 12,500 shares and bought $157,200 worth of shares (30,000 units at $5.24), increasing direct ownership by 25% to 63,288 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      1/29/25 6:13:10 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Chief Financial Officer Young James Emmett was granted 12,500 shares and bought $129,600 worth of shares (24,000 units at $5.40), increasing direct ownership by 135% to 21,726 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      1/29/25 6:03:45 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Large owner Frankenius Equity Ab bought $249,999 worth of shares (62,972 units at $3.97), increasing direct ownership by 1% to 6,230,748 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      12/19/24 6:03:55 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Director Wahlstrom Mats bought $22,750 worth of shares (5,000 units at $4.55), increasing direct ownership by 47% to 15,727 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      11/25/24 5:53:03 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Director Wahlstrom Mats bought $47,057 worth of shares (10,727 units at $4.39) (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      11/22/24 7:11:22 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T bought $75,359 worth of shares (14,815 units at $5.09), increasing direct ownership by 4% to 384,677 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      9/13/24 5:43:14 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T bought $24,850 worth of shares (5,000 units at $4.97), increasing direct ownership by 1% to 369,862 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      9/12/24 7:06:21 PM ET
      $TLSI
      Medical Specialities
      Health Care

    TriSalus Life Sciences Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Manuf, Strategy&Bus Dev. Murphy Sean was granted 15,817 shares, increasing direct ownership by 25% to 79,105 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/19/25 5:54:19 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Chief Financial Officer Young James Emmett was granted 14,762 shares, increasing direct ownership by 68% to 36,488 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/19/25 5:49:46 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CHIEF REGULATORY OFFICER Stevens Jennifer was granted 14,481 shares, increasing direct ownership by 33% to 57,889 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/19/25 5:48:02 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CHIEF OF RESEARCH Cox Bryan F. was granted 11,450 shares, increasing direct ownership by 12% to 108,457 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/19/25 5:45:09 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Chief Commercial Officer Marshak Richard was granted 7,644 shares, increasing direct ownership by 16% to 54,270 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/19/25 5:43:23 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T was granted 21,089 shares, increasing direct ownership by 5% to 465,348 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/19/25 5:41:47 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Chief of Clinical Operations Devlin Jodi was granted 5,272 shares, increasing direct ownership by 19% to 33,397 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/19/25 5:37:35 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Matlin David J

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/11/25 6:04:22 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Wahlstrom Mats

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/11/25 5:59:14 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Large owner Frankenius Equity Ab

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/11/25 5:57:00 PM ET
      $TLSI
      Medical Specialities
      Health Care

    TriSalus Life Sciences Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

      Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated Preferred Stock Exchange to Simplify Capital Structure Private Placement Expected to Fund Business to Profitability Healthcare Focused Long-term Investors Support Strategic Vision TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and techn

      4/30/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

      Revenues of $8.3 Million in Q4 and $29.4 Million for Full-Year 2024, Representing Growth of 44% And 59%, Respectively, Versus the Prior Year Periods Gross Margin of 85% and 86% for Q4 and Full-Year 2024 Reaffirmed 2025 Guidance of Greater than 50% Revenue Growth, Greater than 20% Reduction in Operating Expenses, Positive EBITDA, and Positive Cash flow in H2 2025 Management to host earnings conference call on March 27 at 8:00 a.m. EDT TriSalus Life Sciences Inc., (NASDAQ:TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our inv

      3/27/25 7:30:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

      TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that the Centers for Medicare & Medicaid Services (CMS) has established a new Level II HCPCS code for the TriNav® Infusion System, effective April 1, 2025. This new code, C8004, provides reimbursement clarity for simulation angiograms—commonly known as mapping procedures—conducted prior to transarterial radioembolization (TARE). The introduction of C8004 provides validation of TriNav's growing role in pre-treatment ma

      3/26/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of "Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model"

      TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), TriSalus Life Sciences, which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that company researchers received two JVIR Top Paper Awards for a recent publication, including the JVIR Editor's Award for Distinguished Laboratory Investigation and the JVIR People's Choice Award for Most Downloaded Articles. These awards will be presented at the 2025 Society for Interventional Radiology meeting in Nashville TN. This peer-reviewed study, titled "Intra-arterial Pressure-Enable

      3/6/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces Key Appointments to Board of Directors

      HealthCare Industry Veterans William Valle and Gary Gordon, M.D. add Strategic Expertise in Medical Devices, Reimbursement, and Pancreatic Cancers TriSalus Life Sciences® Inc. (NASDAQ:TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced the appointment of two distinguished HealthCare Industry veterans to its Board of Directors. Mr. William J. Valle and Gary B. Gordon, M.D., Ph.D., joined the Company's Board of Directors, effective as of January 29, 2025. "We are thrilled to welcome William Valle and Dr. Ga

      2/3/25 4:05:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

      TriSalus Life Sciences® Inc. (NASDAQ:TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced that it has requested a drawdown of $10 million under its previously announced $50 million credit agreement with OrbiMed, a healthcare investment firm. Pursuant to the to the Agreement, OrbiMed agreed to provide a term loan facility in an aggregate principal amount of $50 million. The $10 million drawdown became available to TriSalus upon achievement of product revenue-based milestone of $30 million for the trailing 12-

      2/3/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

      Q4 Revenue of approximately $8.3 million represents approximately 44% growth versus Q4 2023 Full year 2024 Revenue of approximately $29.4 million represent approximately 59% growth versus full year 2023 Q4 Operating Cash Flow of approximately ($5.6) million is a notable improvement compared to ($10.8) million in Q3 Company expects to achieve positive full year EBITDA in 2025 and positive Cash Flow during the second half of 2025 Call Scheduled for Thursday, March 27, 2025, at 8:00 a.m. ET TriSalus Life Sciences® Inc. (NASDAQ:TLSI), is announcing preliminary unaudited fourth quarter and full year 2024 financial results and details of the upcoming conference call. Preliminary

      1/23/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

      TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, "Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model," in the peer-reviewed Journal of Vascular and Interventional Radiology. The study, conducted in a transgenic tumor model, highlights the superior performance of the TriNav Infusion System in delivering Embospheres® into liv

      1/9/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Announces Leadership Changes

      James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Strategy and Operations TriSalus Life Sciences, Inc., (NASDAQ:TLSI), an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and our investigational immunotherapy, today announced key updates to its executive leadership team. James (Jim) Young, who previously served as the Company's Senior Vice President of Investor Relations and Treasurer, has been appointed as the Company's Chief Financial Officer. In this role, Mr. Young succeeds Sean Murp

      1/8/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Reports Q3 2024 Financial Results and Provides Business Update

      – Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year – Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025 – Launched TriNav® LV Infusion System and TriGuide™ Guiding Catheter for larger vessels and complex cases, expanding the TriNav system's full access to the $375 million embolization market – Initiated the PROTECT registry trial using the TriNav system to treat multinodular goiters, expanding the TriNav system's reach into the $400 million thyroid embolization market – Presented positive Phase 1 da

      11/14/24 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care

    TriSalus Life Sciences Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by TriSalus Life Sciences Inc.

      SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

      12/4/24 4:00:06 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by TriSalus Life Sciences Inc.

      SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

      10/21/24 8:25:05 AM ET
      $TLSI
      Medical Specialities
      Health Care

    TriSalus Life Sciences Inc. SEC Filings

    See more
    • SEC Form D filed by TriSalus Life Sciences Inc.

      D - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      5/8/25 4:19:26 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by TriSalus Life Sciences Inc.

      EFFECT - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      5/5/25 12:15:25 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form DEF 14A filed by TriSalus Life Sciences Inc.

      DEF 14A - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      4/30/25 5:21:24 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form 425 filed by TriSalus Life Sciences Inc.

      425 - TriSalus Life Sciences, Inc. (0001826667) (Subject)

      4/30/25 8:06:45 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      4/30/25 8:05:38 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form S-3 filed by TriSalus Life Sciences Inc.

      S-3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      4/28/25 4:14:26 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form S-8 filed by TriSalus Life Sciences Inc.

      S-8 - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      4/25/25 5:20:53 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form S-3 filed by TriSalus Life Sciences Inc.

      S-3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      4/25/25 5:19:26 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Inc. filed SEC Form 8-K: Leadership Update

      8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      4/23/25 8:57:06 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Inc. filed SEC Form 8-K: Leadership Update

      8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      4/17/25 4:31:42 PM ET
      $TLSI
      Medical Specialities
      Health Care

    TriSalus Life Sciences Inc. Leadership Updates

    Live Leadership Updates

    See more
    • TriSalus Life Sciences Announces Key Appointments to Board of Directors

      HealthCare Industry Veterans William Valle and Gary Gordon, M.D. add Strategic Expertise in Medical Devices, Reimbursement, and Pancreatic Cancers TriSalus Life Sciences® Inc. (NASDAQ:TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced the appointment of two distinguished HealthCare Industry veterans to its Board of Directors. Mr. William J. Valle and Gary B. Gordon, M.D., Ph.D., joined the Company's Board of Directors, effective as of January 29, 2025. "We are thrilled to welcome William Valle and Dr. Ga

      2/3/25 4:05:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Announces Leadership Changes

      James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Strategy and Operations TriSalus Life Sciences, Inc., (NASDAQ:TLSI), an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and our investigational immunotherapy, today announced key updates to its executive leadership team. James (Jim) Young, who previously served as the Company's Senior Vice President of Investor Relations and Treasurer, has been appointed as the Company's Chief Financial Officer. In this role, Mr. Young succeeds Sean Murp

      1/8/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

      TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB). Dr. Salem is the Chief of Interventional Radiology, and a Professor of Radiology, Surgery, and Medicine in Chicago. Mary Szela, Chief Executive Officer and President of TriSalus, stated, "We are thrilled to welcome Dr. Salem to our SAB. His pioneering work in radiological research and leadership in developing innovative treatments for liver cancer and other

      9/26/24 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

      – Accomplished industry veteran brings deep strategic and operational expertise TriSalus Life Sciences® Inc. (NASDAQ:TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the appointment of Liselotte Hyveled to its Board of Directors. Ms. Hyveled brings over two decades of experience stimulating scientific innovation and advancing pharmaceutical pipelines through research and development excellence. "We are thrilled to welcome Liselotte to the TriSalus Board of Directors as we commercialize the TriNav® Infusion System and progress our pipeline through key milestones in

      5/7/24 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics

      Devlin Brings Significant Expertise in Commercialization, Sales and Marketing TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced that Jodi Devlin has joined the Company as President of TriSalus Therapeutics. In this newly established role, Ms. Devlin will be responsible for developing and executing the go-to-market strategy for TriSalus' SD-101 therapeutic candidate, building the Company's therapeutic marketing operations, working with the clinical team to incorporate commercial and payor needs into the clinical stra

      9/6/23 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care

    TriSalus Life Sciences Inc. Financials

    Live finance-specific insights

    See more
    • TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

      Revenues of $8.3 Million in Q4 and $29.4 Million for Full-Year 2024, Representing Growth of 44% And 59%, Respectively, Versus the Prior Year Periods Gross Margin of 85% and 86% for Q4 and Full-Year 2024 Reaffirmed 2025 Guidance of Greater than 50% Revenue Growth, Greater than 20% Reduction in Operating Expenses, Positive EBITDA, and Positive Cash flow in H2 2025 Management to host earnings conference call on March 27 at 8:00 a.m. EDT TriSalus Life Sciences Inc., (NASDAQ:TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our inv

      3/27/25 7:30:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

      Q4 Revenue of approximately $8.3 million represents approximately 44% growth versus Q4 2023 Full year 2024 Revenue of approximately $29.4 million represent approximately 59% growth versus full year 2023 Q4 Operating Cash Flow of approximately ($5.6) million is a notable improvement compared to ($10.8) million in Q3 Company expects to achieve positive full year EBITDA in 2025 and positive Cash Flow during the second half of 2025 Call Scheduled for Thursday, March 27, 2025, at 8:00 a.m. ET TriSalus Life Sciences® Inc. (NASDAQ:TLSI), is announcing preliminary unaudited fourth quarter and full year 2024 financial results and details of the upcoming conference call. Preliminary

      1/23/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Reports Q3 2024 Financial Results and Provides Business Update

      – Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year – Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025 – Launched TriNav® LV Infusion System and TriGuide™ Guiding Catheter for larger vessels and complex cases, expanding the TriNav system's full access to the $375 million embolization market – Initiated the PROTECT registry trial using the TriNav system to treat multinodular goiters, expanding the TriNav system's reach into the $400 million thyroid embolization market – Presented positive Phase 1 da

      11/14/24 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

      Call Scheduled for Thursday, November 14, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today it will host a conference call and webcast on November 14, 2024, at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2024, and provide a business update. A press release detailing the third quarter results will be issued prior to the call. The event will be webcast live on the investor relations section of TriSalus' website at https://investors.trisaluslifes

      10/31/24 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Reports Q2 2024 Financial Results and Business Update

      Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to prior year periods Reported gross margin of 88% in Q2 2024 and 86% for the six months ended June 30, 2024, compared to 83% and 81%, respectively, in the prior year periods Announces plan to launch the "DELIVER" Program in Q3 2024, clinical trials leveraging the TriNav® Infusion System (TriNav) in complex patient types and aiming to significantly expand the addressable market Expects to report data from phase 1 trials of nelitolimod in uveal melanoma liver metastases and locally advanced pancreatic cancer via its pancreatic infusion technol

      8/15/24 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

      Call Scheduled for Thursday, August 15, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (NASDAQ:TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today it will host a conference call and webcast on August 15, 2024, at 9:00 a.m. ET to discuss financial results for the second quarter ended June 30, 2024, and provide a business update. A press release detailing the second quarter results will be issued prior to the call. The event will be webcast live on the investor relations section of TriSalus' website at https://investors.trisaluslifesci.com/news-events/events-prese

      8/1/24 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Reports Q1 2024 Financial Results and Business Update

      Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 Reported gross margin of 85% in 1Q24 Secured up to $50 million of debt financing with OrbiMed to support TriNav® Infusion System growth initiatives Announced the appointment of Liselotte Hyveled to the Board of Directors Full year sales growth expected to exceed 50% Conference call May 15th at 9:00 a.m. EDT TriSalus Life Sciences Inc., (NASDAQ:TLSI), today announced its financial results for the first quarter ended March 31, 2024, and provided a business update. "I'm proud to highlight our strong start in the first quarter of 2024 with 116% growth in revenues compared to the first quarter of 2023 and si

      5/15/24 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call

      Call Scheduled for Wednesday, May 15, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (NASDAQ:TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today it will host a conference call and webcast on May 15, 2024, at 9:00 a.m. ET to discuss financial results for the first quarter ended March 31, 2024, and provide a business update. A press release detailing the first quarter results will be issued prior to the call. The event will be webcast live on the investor relations section of the TriSalus website at https://investors.trisaluslifesci.com/news-events/events-presenta

      5/6/24 4:58:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

      Reported revenues of $5.7 million in 4Q23, up 77% over prior year Full year revenues of $18.5 million, up 49% over prior year Gross Margin of 90% in 4Q23 and 86% for full year CMS reimbursement granted for the TriNav® Infusion System via assignment of an HCPCS code Real-world data published on TriNav system demonstrating significant improvement in the delivery of therapeutics to liver tumors for patients with higher disease burden Received 510k clearance of TriNav Large and TriGuide systems Completed enrollment in phase 1 clinical trials (100 patients) in several liver indications; data will be analyzed in the second half of 2024 Initiated first-in-man clinical trial o

      4/1/24 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results

      – Q4 sales of approximately $5.7 million represent 77% growth versus 2022 – – Q4 and full year gross margin of approximately 90% and 86% respectively – – Full year 2024 sales growth expected to exceed 50% – – Conference call scheduled for Monday, April 1, 2024, at 9:00 a.m. ET – TriSalus Life Sciences® Inc. (NASDAQ:TLSI) announced today that the Company will host a conference call and webcast on April 1, 2024, at 9:00 a.m. ET to discuss financial results for the fourth quarter and full year ended December 31, 2023, and provide a business update. A press release detailing the fourth quarter and full year results will be issued prior to the call. Preliminary, Unaudited Fourth Quarter an

      3/11/24 5:15:00 PM ET
      $TLSI
      Medical Specialities
      Health Care